External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0% YoY and 3.6% QoQ to Rs 40,903 Cr.</li><li>However, EBITDA is estimated to decline 10% YoY but rise 6.3% QoQ to Rs 8,308 Cr, while adjusted PAT is likely to decline 19.6% YoY but moderately rise by 4.2% sequentially to Rs 4,331 Cr.</li><li>According to IQVIA data, chronic care segments such as cardiovascular and antidiabetic treatments are sustaining their outperformance against the broader Indian Pharmaceutical Market. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0% YoY and 3.6% QoQ to Rs 40,903 Cr.However, EBITDA is estimated to decline 10% YoY but rise 6.3% QoQ to Rs 8,308 Cr, while adjusted PAT is likely to decline 19.6% YoY but moderately rise by 4.2% sequentially to Rs 4,331 Cr.According to IQVIA data, chronic care segments such as cardiovascular and antidiabetic treatments are sustaining their outperformance against the broader Indian Pharmaceutical Market. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharma and Healthcare - Q2FY27E: Result Preview

<ul><li>Global Headwinds &amp; Domestic Resilience (Wait-and-Watch): Global central banks remain in a data-dependent, wait-and-watch posture following recent rate hikes from the Fed and ECB, driven by persistent geopolitical tensions and sticky inflation risks.</li><li>Domestically, strong Q1 GDP growth provides solid structural support. However, markets are closely assessing the inflationary pass-through risks of volatile crude oil, which is further compounded by food inflation and a sub-par monsoon.</li><li>This sets a cautious backdrop ahead of this week’s (5-7th Oct’26) RBI MPC meeting.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Global Headwinds &amp; Domestic Resilience (Wait-and-Watch): Global central banks remain in a data-dependent, wait-and-watch posture following recent rate hikes from the Fed and ECB, driven by persistent geopolitical tensions and sticky inflation risks.Domestically, strong Q1 GDP growth provides solid structural support. However, markets are closely assessing the inflationary pass-through risks of volatile crude oil, which is further compounded by food inflation and a sub-par monsoon.This sets a cautious backdrop ahead of this week’s (5-7th Oct’26) RBI MPC meeting.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Equity Bottom-Up

<ul><li>Healthy Growth in Top-line: Medanta delivered a strong Q1FY27 performance, with revenue rising 26.5% YoY and 12.5% QoQ to Rs 1,304 Cr.</li><li>Growth was driven by a ~21% YoY increase in occupied bed days and a ~5.5% YoY rise in ARPOB to Rs 70,244.</li><li>Reported occupancy stood at ~66%, impacted by the ramp-up at the Noida hospital, while established hospitals continued to sustain healthy momentum. Total bed count increased 6.8% YoY to 2,851.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Healthy Growth in Top-line: Medanta delivered a strong Q1FY27 performance, with revenue rising 26.5% YoY and 12.5% QoQ to Rs 1,304 Cr.Growth was driven by a ~21% YoY increase in occupied bed days and a ~5.5% YoY rise in ARPOB to Rs 70,244.Reported occupancy stood at ~66%, impacted by the ramp-up at the Noida hospital, while established hospitals continued to sustain healthy momentum. Total bed count increased 6.8% YoY to 2,851.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Global Health: Scale-Up Phase Masks Core Performance

<ul><li>Steady Q2FY26 Performance: Medanta delivered a broadly in-line performance in Q2FY26, with revenue of Rs 1,099 Cr, up 15% YoY and 6.6% QoQ.</li><li>Growth was largely driven by an 8% YoY increase in occupied beds and ARPOB growth of 5.5%.</li><li>Reported occupancy stabilised at 64% despite new capacity additions in Ranchi and the commencement of operations at Noida. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Steady Q2FY26 Performance: Medanta delivered a broadly in-line performance in Q2FY26, with revenue of Rs 1,099 Cr, up 15% YoY and 6.6% QoQ.Growth was largely driven by an 8% YoY increase in occupied beds and ARPOB growth of 5.5%.Reported occupancy stabilised at 64% despite new capacity additions in Ranchi and the commencement of operations at Noida. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Global Health Ltd - Strengthening Network with Noida Launch

<ul><li>Record Medanta Q1FY26 Performance: Medanta reported revenue of Rs 1,031 Cr, exceeding estimates by 7%, supported by a 4% YoY increase in ARPOB to Rs 66,584 and a 13% YoY growth in occupied bed days, with occupancy at ~63%. </li><li>EBITDA Margins Growth: EBITDA margins stood at 22.0%, down 265 bps QoQ and 190 bps YoY, impacted by annual salary increments and start-up costs related to the Noida unit. </li><li>Encouraging PAT Growth: Reported PAT stood at Rs 159 Cr, up 44.9% YoY and 20% above estimates. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Record Medanta Q1FY26 Performance: Medanta reported revenue of Rs 1,031 Cr, exceeding estimates by 7%, supported by a 4% YoY increase in ARPOB to Rs 66,584 and a 13% YoY growth in occupied bed days, with occupancy at ~63%. EBITDA Margins Growth: EBITDA margins stood at 22.0%, down 265 bps QoQ and 190 bps YoY, impacted by annual salary increments and start-up costs related to the Noida unit. Encouraging PAT Growth: Reported PAT stood at Rs 159 Cr, up 44.9% YoY and 20% above estimates. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Global Health Ltd - Reports Record Growth; Expansion Momentum

India

Global Health Limited (Medanta) is an India-based multi-specialty tertiary care provider, primarily operating in the North and East regions of India. The company delivers a comprehensive range of healthcare services across various medical specialties, including cardiac sciences, neurosciences, oncology, orthopaedics, liver transplants, and kidney and urology care. Global Health Limited was incorporated on August 13, 2004, and is headquartered in New Delhi, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Global Health (MEDANTA IN)

Pharma and Healthcare - Q2FY27E: Result Preview

We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0%...

Axis Direct

Monthly Quant Report October 2026

Global central banks remain in a data-dependent, wait-and-watch posture following recent rate hikes from the Fed and ECB...

Axis Direct

Global Health: Scale-Up Phase Masks Core Performance

The stock remains attractive on the back of strong operational performance, robust network expansion, and a healthy balance sheet, supporting...

Axis Direct

Global Health Ltd - Strengthening Network with Noida Launch

Steady Q2FY26 Performance: Medanta delivered a broadly in-line performance in Q2FY26, with revenue of Rs 1,099 Cr, up 15% YoY and 6.6% QoQ.

Axis Direct

Global Health Ltd - Reports Record Growth; Expansion Momentum

Medanta reported revenue of Rs 1,031 Cr, exceeding estimates by 7%, supported by a 4% YoY increase in ARPOB to Rs 66,584 and a 13% YoY growth in...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)